Literature DB >> 6413486

Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.

M J Maslow, A Rosenberg, A A Pollock, R A Press, D Silverman, W El-Sadr, A S Richmond, M S Simberkoff, J J Rahal.   

Abstract

Sixteen patients with serious Gram-negative bacillary infections were treated with intravenous ceftazidime, 2 g every 8 h. The majority of patients had bacteraemia or pneumonitis or both. Ten patients were cured and six improved. Seven of ten patients infected with Pseudomonas aeruginosa were cured, and three improved. No adverse reactions occurred. Four strains of Ps. aeruginosa became resistant to ceftazidime in patients who were cured or improved clinically. Ceftazidime is effective as single drug therapy for serious Gram-negative infections, including those due to Ps. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413486     DOI: 10.1093/jac/12.suppl_a.213

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

Authors:  S M Shrivastava; S K Shukla; M Chaudhary
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

Review 2.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

3.  Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 4.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.